- 9
- 9MW2821 (anti-NECTIN4 antibody-drug conjugate)
-
NECTIN4
- A
- A947 (SMARCA2-selective PROTAC degrader)
-
SMARCA4
- ABBV-400 (anti-cMET antibody-drug conjugate)
-
MET
- ABBV-637 + Osimertinib
-
EGFR
- ABBV-706 (antibody-drug conjugate, SEZ6-targeting)
-
SEZ6
- Abemaciclib (CDK4/6 inhibitor)
-
CDKN2A, NF2, CCND2, CCND3, CDK4, CCNE1, CDK6, ESR1 (ER)+MDM2, ESR1 (ER)+TP53, FAT1, RB1
- Abemaciclib + Anastrazole
-
ERBB2 (HER2)+ESR1 (ER)
- Abemaciclib + AZD8421
-
ESR1 (ER)+TP53
- Abemaciclib + Fulvestrant
-
ESR1 (ER)+ERBB2 (HER2)
- Abemaciclib + Letrozole
-
ERBB2 (HER2)+ESR1 (ER)
- Abemaciclib + LY3214996
-
NF1
- Abiraterone acetate (CYP17A1 inhibitor)
-
AR
- Abiraterone Acetate + Goserelin
-
AR
- Abiraterone Acetate + Leuprorelin
-
AR
- Abiraterone Acetate + Triptorelin
-
AR
- ABN401 (MET inhibitor, type 1)
-
MET
- ABT-806 (anti-EGFR monoclonal antibody)
-
EGFR
- ACBI3 (KRAS PROTAC degrader)
-
KRAS
- Acimtamig (bispecific CD30/CD16A antibody)
-
TNFRSF8 (CD30)
- Adagrasib (KRAS G12C inhibitor)
-
KRAS, KRAS+STK11, ALK, BRAF, EGFR, FGFR3, HRAS, MAP2K1, MET, NF1, NRAS, PIK3CA, PIK3R1, PTEN, RAF1, RET, RIT1
- Adagrasib + Cetuximab
-
KRAS
- Adagrasib + Pembrolizumab
-
KRAS
- Adavosertib (WEE1 inhibitor)
-
CCNE1, TP53, TP53+KRAS, ATRX
- ADCT-701 (anti-DLK1 antibody-drug conjugate)
-
DLK1
- ADRX-0706 (anti-NECTIN4 antibody-drug conjugate)
-
NECTIN4
- ADT-007
-
HRAS, KRAS, NRAS
- Afatinib (EGFR inhibitor, second generation, ERBB2 inhibitor, second generation)
-
EGFR, ERBB2 (HER2), ERBB3, ERBB4, NRG1, EGFR+ALK, EGFR+RB1, EGFR+RET, EGFR+ROS1, EGFR+TP53, KRAS, MET
- Afatinib + Bevacizumab
-
EGFR, EGFR+ERBB2 (HER2)
- Afatinib + Selumetinib
-
KRAS+ERBB3
- Afatinib + Temozolomide
-
EGFR
- AG-270 (MAT2A inhibitor)
-
MTAP
- Agerafenib (BRAF inhibitor, BRAF V600 inhibitor, RET inhibitor)
-
RET
- Alectinib (ALK inhibitor, second generation, ALK/RET inhibitor)
-
ALK, LTK, RET
- Alisertib + Pembrolizumab
-
RB1
- Alkylating agent
-
MGMT
- Alpelisib (PI3K alpha inhibitor)
-
PIK3CA
- Alpelisib + Fulvestrant
-
PIK3CA
- Alpelisib + Letrozole
-
MAP3K1+PIK3CA
- Alrizomadlin + Pembrolizumab
-
ATM+TP53, STK11
- ALTA-2618
-
AKT1
- Amatuximab (anti-MSLN monoclonal antibody)
-
MSLN
- AMB-05X (anti-CSF1R monoclonal antibody)
-
CSF1
- AMG-193 (PRMT5 inhibitor, MTA-co-operative)
-
MTAP
- AMG-596 (bispecific T-cell engager, EGFRvIII-targeting)
-
EGFR
- AMG-650 (KIF18A inhibitor)
-
TP53
- AMG 193 (PRMT5 inhibitor, MTA-co-operative)
-
MTAP
- AMG 337 (MET inhibitor)
-
MET
- Amivantamab (bispecific cMET/EGFR antibody)
-
EGFR, EGFR+MET, MET
- Amivantamab + Carboplatin + Pemetrexed
-
EGFR
- Amivantamab + Carboplatin + Pemetrexed + Lazertinib
-
EGFR
- Amivantamab + Lazertinib
-
EGFR, EGFR+EGFR, EGFR+MET, MET
- AMT-116 (anti-CD44v9 antibody-drug conjugate)
-
CD44
- AMT-562 (anti-ERBB3 antibody-drug conjugate)
-
ERBB3
- AMX-818 (bispecific T-cell engager, ERBB2-targeting)
-
ERBB2 (HER2)
- Anastrozole (aromatase inhibitor)
-
ESR1 (ER), PGR
- Anastrozole + Palbociclib
-
ESR1 (ER)
- Androgen receptor antagonist
-
AR, AURKA, MYCN, RB1, TP53
- Anetumab Ravtansine (anti-mesothelin antibody-drug conjugate)
-
MSLN
- Anlotinib (FGFR/KIT/PDGFR/VEGFR inhibitor)
-
FGFR3
- Anti-androgen
-
AR
- Anti-CTLA-4 monoclonal antibody
-
EPHA7, CDKN2A, HLA-A
- anti-ERBB2 monoclonal antibody
-
ERBB2 (HER2)
- Anti-ERBB3 monoclonal antibody
-
ERBB3
- Anti-PD-1 monoclonal antibody
-
ARID1A, ARID2, B2M, CD274 (PD-L1), CDK12, DNMT3A, EPHA7, LRP1B, MLH1, MSH2, MSH6, PDCD1LG2, PMS2, POLD1, POLE, PRKDC, Tumour Mutational Burden (TMB), ALK, CDKN2A, EGFR, HLA-A, Mismatch repair (MMR), STK11+KRAS
- Anti-PD-1 monoclonal antibody + Anti-CTLA-4 monoclonal antibody
-
ARID2, BRD7, EPHA7, PBRM1, CDKN2A
- Anti-PD-L1 monoclonal antibody
-
ARID1A, B2M, CD274 (PD-L1), DNMT3A, EPHA7, LRP1B, MLH1, MSH2, MSH6, PMS2, POLD1, POLE, PRKDC, Tumour Mutational Burden (TMB), ALK, CDKN2A, EGFR, HLA-A, Mismatch repair (MMR), STK11+KRAS
- Anti-PD-L1 monoclonal antibody + Anti-CTLA-4 monoclonal antibody
-
CDKN2A
- Apalutamide (antiandrogen, nonsteroidal, second generation)
-
AR, AURKA, MYCN, RB1, TP53
- Apalutamide + Goserelin
-
AR
- Apatinib + Gefitinib
-
EGFR
- APG-2449 (FAK/ALK/ROS1 inhibitor, FAK inhibitor, ALK inhibitor, third generation)
-
ALK, ROS1
- Aromatase Inhibitor
-
ESR1 (ER)
- Arsenic trioxide (arsenic, GLI2 inhibitor)
-
PTCH1, SMO
- ARV-471 (ER PROTAC degrader)
-
ESR1 (ER)+ERBB2 (HER2)
- ARV-766 (AR PROTAC degrader)
-
AR
- Asciminib (BCR-ABL1 inhibitor)
-
ABL1
- ASP3082 (KRAS G12D degrader)
-
KRAS
- Atezolizumab (anti-PD-L1 monoclonal antibody)
-
CD274+EGFR+ALK, CD274 (PD-L1), Tumour Mutational Burden (TMB), ARID1A, ARID1B, CD8, CDK12, CXCL13, Microsatellite Instability (MSI), PBRM1, SMARCA4, SMARCB1, ALK, CRKL, EGFR
- Atezolizumab + Carboplatin + Paclitaxel
-
Mismatch repair (MMR)
- Atezolizumab + Carboplatin + Paclitaxel + Bevacizumab
-
CD274 (PD-L1)
- Atezolizumab + Cobimetinib
-
KRAS, Microsatellite Instability (MSI)
- Atezolizumab + Cobimetinib + Vemurafenib
-
BRAF
- Atezolizumab + Docetaxel + Cisplatin + Fluorouracil
-
CD274 (PD-L1)
- Atezolizumab + Nab-paclitaxel
-
CD274 (PD-L1), Molecular subtype, Tumour microenvironment
- Atezolizumab + Rucaparib
-
BRCA1, BRCA2
- Atezolizumab + Tiragolumab
-
CD274 (PD-L1)
- Atezolizumab + Vemurafenib + Cobimetinib
-
BRAF
- ATX968 (DHX9 inhibitor)
-
Microsatellite Instability (MSI), Mismatch repair (MMR)
- Aumolertinib (EGFR inhibitor, third generation)
-
EGFR, PIK3CA
- Avapritinib (KIT D816V inhibitor, KIT inhibitor, ATP-competitive, PDGFRA inhibitor)
-
KIT (CD117), PDGFRA
- Avelumab (anti-PD-L1 monoclonal antibody)
-
CD274 (PD-L1), HLA-A
- Avelumab + Axitinib
-
PBRM1, HLA-A
- Avelumab + Carboplatin + Paclitaxel
-
ARID1A, Microsatellite Instability (MSI)
- Avutometinib (RAF/MEK clamp)
-
KRAS
- Avutometinib + BI-3406
-
NF1
- Avutometinib + Defactinib
-
KRAS
- Axitinib (VEGFR/PDGFR inhibitor, KIT inhibitor, ATP-competitive)
-
KIT (CD117)
- Azacitidine + Venetoclax
-
IDH1, IDH2
- AZD1390 + GSK126
-
BAP1
- AZD1390 + Radiotherapy
-
ATM
- AZD3463 (ALK inhibitor, IGF1R inhibitor, ROS1 inhibitor)
-
ROS1
- AZD4547 (FGFR1/2/3 inhibitor, FGFR1/2/3 inhibitor, reversible)
-
FGFR1, FGFR2, FGFR3, MET
- AZD6422 (autologous CAR-T-cell therapy, CLDN18.2-targeting)
-
CLDN18
- AZD7762 (CHEK1 inhibitor)
-
RB1
- AZD8055 (mTORC1/mTORC2 inhibitor)
-
EIF1AX, EIF1AX+NRAS
- AZD8055 + JQ1
-
EIF1AX, EIF1AX+NRAS
- AZD8055 + Trametinib
-
EIF1AX, EIF1AX+NRAS
- AZD8186 (PI3K beta inhibitor)
-
PTEN
- AZD9496 (selective estrogen receptor degrader)
-
ESR1 (ER)
- AZD9592 (anti EGFR/cMET antibody-drug conjugate)
-
EGFR
- AZD9833 (selective estrogen receptor degrader)
-
ESR1 (ER)
- Azenosertib (WEE1 inhibitor)
-
CCNE1, FBXW7
- B
- Balstilimab + Zalifrelimab
-
CD274 (PD-L1)
- BAT8008 (anti-Trop2 antibody-drug conjugate)
-
TACSTD2 (Trop2)
- BAY-1895344 (ATR inhibitor)
-
ATM
- BAY1436032 (IDH1 R132 inhibitor)
-
IDH1
- BAY2010112 (bispecific T-cell engager, PSMA-targeting)
-
PSMA
- BBO-8520 (KRAS G12C inhibitor)
-
KRAS
- BBO-10203 (PI3K alpha-RAS breaker)
-
ERBB2 (HER2)
- BC3195 (anti-CDH3 antibody-drug conjugate)
-
EGFR
- BCL6 inhibitor
-
BCL6
- BDC-4182 (anti-CLDN18.2 immune-stimulating antibody conjugate, TLR7/8 agonist)
-
CLDN18
- Belantamab mafodotin (anti-BCMA-immunoconjugate)
-
TNFRSF17
- Belantamab mafodotin + Bortezomib + Dexamethasone
-
TNFRSF17
- Belantamab mafodotin + Pomalidomide + Dexamethasone
-
TNFRSF17
- Belvarafenib (pan-RAF inhibitor)
-
ARAF, BRAF, NRAS
- Belvarafenib + Cobimetinib
-
NRAS
- Belzutifan (HIF2a inhibitor)
-
VHL, EPAS1
- Bemarituzumab (anti-FGFR2b monoclonal antibody)
-
FGFR2
- Bemarituzumab + FOLFOX
-
FGFR2
- Benmelstobart + Anlotinib
-
CD274 (PD-L1)
- Berzosertib (ATR inhibitor)
-
PBRM1, POLD1, ARID1A, ATM, ATRX, FBXW7, MYC, SDHA, SDHB, SDHC, SDHD
- Berzosertib + Irinotecan
-
ATM, TP53
- Berzosertib + PF-477736
-
CHEK1
- BET inhibitor
-
BRD4, MYC, MYCN, PBRM1, SMARCA4
- Bevacizumab + erlotinib
-
FH
- Bezuclastinib (KIT D816V inhibitor, KIT inhibitor, type 1)
-
KIT (CD117), PDGFRA
- BG-60366 (EGFR CDAC degrader)
-
EGFR
- BG-C477 (anti-CEACAM5 antibody-drug conjugate)
-
CEACAM5
- BGB-3245 (RAF dimer inhibitor)
-
BRAF, KRAS, NRAS
- BGB-53038 (pan-KRAS inhibitor)
-
KRAS
- BGB-B2033 (anti-GPC3 monoclonal antibody)
-
GPC3
- BGB659 (RAF inhibitor, type 2)
-
BRAF
- BGB3245
-
BRAF
- BI-2493
-
HRAS, KRAS, NRAS
- BI-2865
-
HRAS, KRAS, NRAS
- BI-7273 (BRD9 inhibitor)
-
SS18
- BI-1701963
-
KRAS
- BI-1810631 (ERBB2 inhibitor, second generation)
-
ERBB2 (HER2)
- BI 764532 (bispecific T-cell engager, DLL3-targeting)
-
DLL3
- Bicalutamide (antiandrogen, nonsteroidal, first generation)
-
AR
- Binimetinib (MEK inhibitor)
-
KRAS, NRAS, ERBB3
- Binimetinib + Darovasertib
-
GNA11, GNAQ
- Binimetinib + Encorafenib
-
BRAF, KRAS
- Binimetinib + Encorafenib + Cetuximab
-
BRAF
- Birabresib (BET inhibitor)
-
BRD3, BRD4, NUTM1
- bispecific ERBB2/CD3 monoclonal antibody
-
ERBB2 (HER2)
- Bispecific PSMA/CD3 antibody
-
PSMA
- Blinatumomab (bispecific T-cell engager, CD19-targeting)
-
CD19
- BMS-754807 (IGF1R inhibitor)
-
IRS2, IRS2+BRAF, IRS2+KRAS
- BMS-986365 (dual AR degrader antagonist)
-
AR
- BNT142 (bispecific T-cell engager, CLDN6-targeting)
-
CLDN6
- BNT211 (CAR-T-cell therapy, mRNA vaccine, CLDN6-targeting)
-
CLDN6
- BOS-342 (bispecific GPC3/4-1BB antibody)
-
GPC3
- BOS172738 (RET-selective inhibitor)
-
RET
- Bosutinib (BCR-ABL1 inhibitor, second generation, SRC inhibitor)
-
ABL1, NF1, WT1
- Brentuximab Vedotin (anti-CD30 antibody-drug conjugate)
-
TNFRSF8 (CD30)
- Brigatinib (ROS1 inhibitor, ALK inhibitor, second generation, EGFR/FLT3/FER/ROS1/IGF1R inhibitor)
-
ALK, NF2, ROS1, LTK
- Brigimadlin (MDM2 inhibitor)
-
MDM2+TP53
- BRY812 (anti-LIV1 antibody-drug conjugate)
-
SLC39A6
- BSJ-03-123 (CDK6 PROTAC degrader)
-
H3F3A
- BTRC4017A (bispecific T-cell engager, ERBB2-targeting)
-
ERBB2 (HER2)
- Buparlisib (pan-PI3K inhibitor, PI3K alpha inhibitor)
-
PIK3CA, PIK3R1, PTEN, TSC1
- Buparlisib + Fulvestrant
-
PIK3CA, PIK3CA+ESR1 (ER)+ERBB2 (HER2)
- Buparlisib + Letrozole
-
MAP3K1+PIK3CA
- Buparlisib + Tamoxifen
-
PIK3CA
- BWA-522
-
AR
- C
- Cabozantinib (AXL/MET/RET/VEGFR/ROS1/KIT inhibitor, AXL inhibitor, MET inhibitor, type 2, RET inhibitor, VEGFR2 inhibitor, ROS1 inhibitor, KIT inhibitor)
-
KIT (CD117), NF1, RET, SDHB, MET, ROS1, MDM2
- Cabozantinib + Nivolumab
-
FH, NF2, SETD2
- Cadonilimab + Anlotinib
-
CD274 (PD-L1)
- Camizestrant (selective estrogen receptor degrader)
-
ESR1 (ER), ESR1 (ER)+ERBB2 (HER2)
- Camizestrant + Abemaciclib
-
ESR1 (ER)
- Camizestrant + Palbociclib
-
ESR1 (ER)
- Camizestrant + Ribociclib
-
ESR1 (ER)
- Camonsertib (ATR inhibitor)
-
ATM, BRCA1, BRCA2, CDK12, RAD51C, SETD2
- Camrelizumab (anti-PD-1 monoclonal antibody)
-
CD274 (PD-L1)
- Canertinib (EGFR/ERBB2 inhibitor)
-
ERBB2 (HER2)
- Capecitabine + Bevacizumab
-
Consensus molecular subtype
- Capecitabine + Temozolomide
-
MGMT
- Capecitabine + Trastuzumab + Tucatinib
-
ERBB2 (HER2)
- Capivasertib (pan-AKT inhibitor)
-
AKT1, ARID1A
- Capivasertib + Docetaxel
-
PTEN
- Capivasertib + Fulvestrant
-
AKT1, PIK3CA, PTEN
- Capivasertib + Paclitaxel
-
AKT1, PIK3CA, PTEN, ESR1 (ER)+PIK3CA
- Capmatinib (MET inhibitor, type 1)
-
MET, NF1+MET, EGFR, ERBB3
- Capmatinib + Gefitinib
-
EGFR+MET
- Capmatinib + Trametinib
-
NF1+MET
- Carboplatin (platinum-based antineoplastic agent)
-
EMSY
- Carboplatin + Etoposide
-
BRAF, MYC, MYCL, MYCN
- Carboplatin + Paclitaxel + Bevacizumab
-
TP53
- Carboplatin + Paclitaxel + Trastuzumab
-
ERBB2 (HER2)
- Carboxyamidotriazole Orotate + Temozolomide
-
EGFR
- CARv3-TEAM-E T cell
-
EGFR
- CB-103 (CSL-NICD transcription factor complex inhibitor)
-
NOTCH1
- CC-94676
-
AR
- CCT128930 (AKT2 inhibitor)
-
AKT2
- Cemiplimab (anti-PD-1 monoclonal antibody)
-
CD274 (PD-L1)
- Ceralasertib (ATR inhibitor)
-
ARID1A, ATM, ATR, PBRM1, TP53
- Ceralasertib + Adavosertib
-
CCNE1
- Ceralasertib + Bendamustine
-
ATM, TP53
- Ceralasertib + Chlorambucil
-
ATM, TP53
- Ceralasertib + Fludarabine
-
ATM, TP53
- Ceralasertib + Ibrutinib
-
ATM, TP53
- Ceralasertib + Olaparib
-
BRCA1, BRCA2, Homologous Recombination Deficiency Score (HRD), ATM, ARID1A
- Ceritinib (ALK/ROS1/IGF1R inhibitor)
-
ALK, ROS1, IRS2, LTK, RET
- Cetuximab (anti-EGFR monoclonal antibody)
-
KRAS+NRAS, BRAF, EGFR, KRAS, NRAS, ARID1A, ERBB2 (HER2), ERBB4, HRAS, KRAS+NRAS+BRAF, MAP2K1, MET, NF1
- Cetuximab + FOLFIRI
-
KRAS+NRAS, BRAF, KRAS, NRAS, EGFR, HRAS
- Cetuximab + Irinotecan
-
KRAS+NRAS, BRAF, KRAS, NRAS, EGFR, ERBB2 (HER2), HRAS
- Cetuximab + irinotecan
-
ERBB2 (HER2)
- Cetuximab + Irinotecan + Vemurafenib
-
BRAF
- CFT1946 (BRAF V600E degrader)
-
BRAF
- Cinrebafusp alfa (bispecific ERBB2/4-1BB antibody)
-
ERBB2 (HER2)
- Cisplatin (platinum-based antineoplastic agent)
-
BRCA1, BRCA2, CDK12, EMSY, ERCC1, ERCC2, FANCA, Homologous Recombination Deficiency Score (HRD), Chromosome, SMARCA4
- Cisplatin + Etoposide
-
BRAF, MYC, MYCL, MYCN
- Cisplatin + Gemcitabine
-
BRCA1, BRCA2, PALB2
- Cisplatin + Gemcitabine + Veliparib
-
PALB2
- Cisplatin + Veliparib
-
BRCA1, BRCA2
- Cobimetinib (MEK inhibitor)
-
BRAF, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, ARAF, HRAS
- Copanlisib (pan-PI3K inhibitor, PI3K alpha/PI3K delta inhibitor)
-
PIK3CA
- Crenolanib (FLT3 inhibitor, PDGFRA inhibitor, PDGFRB inhibitor)
-
KIT (CD117), PDGFRA
- Crizotinib (ALK inhibitor, first generation, MET inhibitor, type 1, ROS1 inhibitor)
-
ALK, ROS1, MET, CDH1, LTK, MET+KRAS, EGFR, KRAS, KRAS+MET, MET+TP53, NF1, RET, ROS1+MET
- Crizotinib (ALK inhibitor, first generation, MET inhibitor, type 1, ROS1 inhibitor)
-
MET
- Crizotinib + Cetuximab
-
MET
- Crizotinib + Darovasertib
-
GNA11, GNAQ
- CX-5461 (RNA polymerase I transcription inhibitor)
-
BRCA1, BRCA2, MYC, MYCL, MYCN
- CX-5461 + Olaparib
-
BRCA1, BRCA2
- CYH33 (PI3K alpha inhibitor)
-
PIK3CA
- CYP17A1 inhibitor
-
AR, AURKA, MYCN, RB1, TP53
- D
- D3S-001 (KRAS G12C inhibitor)
-
KRAS
- Dabrafenib (BRAF V600 inhibitor)
-
BRAF, MAP2K1+BRAF, MAP2K2, NRAS
- Dabrafenib + Panitumumab
-
KRAS
- Dabrafenib + Trametinib
-
BRAF, BRAF+KRAS, BRAF+MAP2K1, BRAF+NRAS, BRAF+PTEN, MAP2K1, MAP2K2, MAPK1 (ERK2), MAPK3 (ERK1), NRAS
- Dabrafenib + Trametinib + Omipalisib
-
MAP2K2
- Dabrafenib + Trametinib + Osimertinib
-
EGFR+BRAF
- Dacomitinib (EGFR inhibitor, second generation)
-
EGFR, ERBB2 (HER2), ERBB4, MET
- Daratumumab + Bortezomib + Dexamethasone
-
CD38
- Daratumumab + Bortezomib + Lenalidomide + Dexamethasone
-
CD38
- Daratumumab + Hyaluronidase-fihj
-
CD38
- Daratumumab + Lenalidomide + Dexamethasone
-
CD38
- Darovasertib (PKC inhibitor)
-
GNA11, GNAQ, PRKCA, PRKCB
- Dasatinib (BCR-ABL1 inhibitor, second generation, KIT inhibitor, PDGFRA inhibitor, SRC inhibitor, YES1 inhibitor)
-
ABL1, PDGFRA, ARID1A, BAP1, NF1, PTPN11, WT1
- Dasatinib + Blinatumomab
-
ABL1
- Datopotamab Deruxtecan (anti-Trop2 antibody-drug conjugate)
-
EGFR, TACSTD2 (Trop2)
- DB-1303, ARX788
-
ERBB2 (HER2)
- DB-1310 (anti-ERBB3 antibody-drug conjugate)
-
EGFR
- DB-1419 (bispecific B7H3/PD-L1 antibody)
-
CD274 (PD-L1), CD276 (B7-H3)
- Defactinib (FAK inhibitor)
-
NF2
- Depatuxizumab mafodotin (anti-EGFR/PBD antibody-drug conjugate)
-
EGFR
- Derazantinib (FGFR1/2/3 inhibitor, FGFR1/2/3 inhibitor, reversible)
-
FGFR2
- Dinaciclib (CDK1/2/5/9 inhibitor, CDK12 inhibitor)
-
MCL1
- Dinaciclib + MK2206
-
CCNE1
- Disitamab vedotin + Toripalimab
-
ERBB2 (HER2)
- Divarasib (KRAS G12C inhibitor)
-
KRAS, ALK, BRAF, EGFR, ERBB2 (HER2), HRAS, MAP2K1, MET, MYC, NF1, NRAS, PIK3CA, PIK3R2, PTEN, RB1, RET, ROS1
- Divarasib + Cetuximab
-
KRAS, ALK, BRAF, EGFR, ERBB2 (HER2), HRAS, MAP2K1, MET, MYC, NF1, NRAS, PIK3CA, PIK3R2, PTEN, RET, ROS1
- DM002 (bispecific-ERBB3/MUC1 antibody-drug conjugate)
-
MUC1
- Docetaxel + Trastuzumab
-
ERBB2 (HER2)
- Dostarlimab (anti-PD-1 monoclonal antibody)
-
Microsatellite Instability (MSI), Mismatch repair (MMR)
- Dostarlimab + Carboplatin + Paclitaxel
-
Microsatellite Instability (MSI), Mismatch repair (MMR)
- Dovitinib (FGFR1/2/3/PDGFRB/VEGFR inhibitor)
-
FGFR2, FGFR3, FGFR1
- DS-3939
-
MUC1
- DS-6000a (anti-CDH6 antibody-drug conjugate)
-
CDH6
- DS-9606a (anti-CLDN6 monoclonal antibody)
-
CLDN6
- Duligotuzumab + FOLFIRI
-
KRAS+NRAS
- Durvalumab (anti-PD-L1 monoclonal antibody)
-
CD274 (PD-L1), Mismatch repair (MMR), POLD1, POLE, ARID1A, ARID1B, CDK12, PBRM1, SMARCA4, SMARCB1, Microsatellite Instability (MSI)
- Durvalumab + Olaparib
-
BRCA1, ATM, BARD1, BRCA2, BRIP1, CDK12, RAD51C
- Durvalumab + Paclitaxel + Trastuzumab deruxtecan
-
ERBB2 (HER2)
- Durvalumab + Savolitinib
-
HGF, MET
- Durvalumab + Tremelimumab
-
Tumour Mutational Burden (TMB), CDK12, Tumour Mutational Burden+Microsatellite, Tumour Mutational Burden+Mismatch repair
- DYP688 (GNAQ/GNA11 inhibitor)
-
GNA11, GNAQ
- DZD9008 (EGFR inhibitor, exon 20 selective, ERBB2 inhibitor, exon 20 selective)
-
EGFR
- E
- E-EDV-D682 (EnGeneIC Dream Vector-nanocells-delivered, EGFR-targeting)
-
EGFR
- E7090 (FGFR1/2/3 inhibitor, FGFR1/2/3 inhibitor, reversible)
-
FGFR2
- eFT508 (MNK inhibitor)
-
MYD88
- EGFR inhibitor,exon 20 selective
-
EGFR
- Elacestrant (selective estrogen receptor degrader)
-
ERBB2 (HER2)+ESR1 (ER), ESR1 (ER)
- Elotuzumab + Lenalidomide + Dexamethasone
-
SLAMF7
- ELVN-002 (ERBB2 inhibitor, exon 20 selective)
-
ERBB2 (HER2)
- Elzovantinib (MET/SRC/CSF1R inhibitor)
-
MET
- Emactuzumab (anti-CSF1R monoclonal antibody)
-
CSF1
- Enasidenib (IDH2 inhibitor)
-
IDH2
- Enasidenib + Azacitidine
-
IDH2
- Encorafenib (BRAF V600 inhibitor)
-
BRAF
- Encorafenib + Binimetinib
-
BRAF
- Encorafenib + Binimetinib + Cetuximab
-
BRAF+KRAS, BRAF+MAP2K1, BRAF+MET, BRAF+NRAS
- Encorafenib + Capamatinib
-
BRAF+MET
- Encorafenib + Capmatinib
-
BRAF+MET
- Encorafenib + Cetuximab
-
BRAF, BRAF+KRAS, BRAF+MAP2K1, BRAF+MET, BRAF+NRAS
- Encorafenib + Cetuximab + mFOLFOX6
-
BRAF
- Encorafenib + Osimertinib
-
BRAF+EGFR
- Encorafenib, Dabrafenib
-
BRAF
- Enfortumab Vedotin (anti-NECTIN4 antibody-drug conjugate)
-
NECTIN4
- Enfortumab vedotin (anti-NECTIN4 antibody-drug conjugate)
-
NECTIN4
- Enfortumab vedotin + Pembrolizumab
-
NECTIN4
- Enobosarm (selective androgen receptor modulator)
-
AR+ESR1 (ER)
- Ensartinib (ALK inhibitor, third generation, ROS1 inhibitor)
-
ALK, ROS1, EGFR, ERBB2 (HER2), KRAS
- Entinostat + Exemestane
-
ESR1 (ER)
- Entrectinib (ALK inhibitor, third generation, TRK inhibitor, first generation, ROS1 inhibitor)
-
ROS1, NTRK1, NTRK2, NTRK3, ALK, LTK, KRAS
- Enzalutamide (antiandrogen, nonsteroidal, second generation)
-
AR, AURKA, MYCN, RB1, TP53
- Enzalutamide + Talazoparib
-
BRCA1, BRCA2
- EO1001 (ERBB2 inhibitor, second generation, EGFR inhibitor, second generation)
-
EGFR
- EPI-7386 (antiandrogen, AR NTD inhibitor)
-
AR
- Eprenetapopt + Azacitidine
-
TP53
- EPZ011989 (EZH2 inhibitor)
-
BAP1
- EPZ015666 (PRMT5 inhibitor)
-
CDKN2A+MTAP
- EPZ6438 (EZH2 inhibitor)
-
H3F3A
- ERBB2 inhibitor
-
ERBB2 (HER2)
- Erdafitinib (pan-FGFR inhibitor, pan-FGFR inhibitor, reversible)
-
FGFR2, FGFR3, FGFR1
- Erdafitinib, Pemigatinib
-
FGFR2
- Erloginib
-
ERBB2 (HER2)
- Erlotinib (EGFR inhibitor, first generation)
-
EGFR, ERRFI1, MAPK1 (ERK2), BCL2L11, BRAF, EGFR+ALK, EGFR+RB1, EGFR+RET, EGFR+ROS1, EGFR+TP53, ERBB2 (HER2), MET
- Erlotinib + Osimertinib
-
EGFR
- ERX-315 (benzamide, ER alpha-targeting)
-
ESR1 (ER)
- ETC-159 (PORCN inhibitor)
-
RNF43
- Everolimus (mTORC1 inhibitor)
-
TSC1, TSC2, FGFR1, MTOR, NF2, PTEN, STK11, PIK3CA
- Everolimus + Docetaxel
-
NF2
- Everolimus + Exemestane
-
EIF4EBP1
- Everolimus + Letrozole
-
ESR1 (ER)
- Everolimus + Trastuzumab
-
PTEN+ERBB2 (HER2)
- Exarafenib (pan-RAF inhibitor)
-
BRAF, NRAS
- Exemestane (aromatase inhibitor)
-
ESR1 (ER), PGR
- Exemestane + Palbociclib
-
ESR1 (ER)
- F
- Fadraciclib (CDK2/CDK9 inhibitor)
-
CCNE1, MCL1
- Famitinib + Camrelizumab + Nab-paclitaxel
-
Tumour microenvironment
- FCN-159 (MEK inhibitor)
-
NF1
- Fedratinib (JAK2-selective inhibitor)
-
JAK2
- FG-M108 + Nab-paclitaxel + Gemcitabine
-
CLDN18
- FHD-286 (SMARCA4/SMARCA2 inhibitor)
-
POU2F3
- FHD-609 (BRD9 PROTAC degrader)
-
POU2F3, SMARCB1, SS18
- Ficlatuzumab + Cetuximab
-
Human Papillomavirus Status, MET
- Fisogatinib (FGFR4 inhibitor, FGFR4 inhibitor, irreversible)
-
FGF19, FGFR4
- Fluorouracil + Panitumumab
-
EGFR
- Flutamide (antiandrogen, nonsteroidal, first generation)
-
AR
- FOLFIRI + Cetuximab
-
KRAS+NRAS, Consensus molecular subtype, EGFR, NRAS
- FOLFIRINOX (Fluorouracil + Oxaliplatin + Irinotecan)
-
PALB2, RAD51C
- FOLFOX + ABT-806
-
EGFR
- FOLFOX + Bevacizumab + Durvalumab + Oleclumab
-
Microsatellite instability+Mismatch repair
- FOLFOX + Panitumumab
-
KRAS+NRAS, BRAF, KRAS, NRAS, EGFR, HRAS
- FOLFOXIRI + Bevacizumab + Atezolizumab
-
Immunoscore IC, Mismatch repair (MMR), Tumour Mutational Burden (TMB)
- FORE8394 (RAF dimer inhibitor)
-
BRAF, RAF1
- Foretinib (MET inhibitor, type 2, ROS1 inhibitor)
-
CDH1, FLT3, MET
- Fulvestrant (selective estrogen receptor degrader)
-
ESR1 (ER), ARID1A
- Fulvestrant + Abemaciclib
-
ESR1 (ER)
- Fulvestrant + Alpelisib
-
PIK3CA, PIK3CA+FGFR1, PIK3CA+FGFR2
- Fulvestrant + Neratinib
-
ERBB2 (HER2)
- Fulvestrant + Palbociclib
-
ESR1 (ER), CCNE1, FGFR1
- Fulvestrant + Palbociclib + Erdafitinib
-
FGFR1
- Fulvestrant + Ribociclib
-
FGFR1, FGFR2
- Furmonertinib (EGFR inhibitor, third generation, EGFR inhibitor, exon 20 selective, ERBB2 inhibitor, exon 20 selective)
-
EGFR
- Futibatinib (pan-FGFR inhibitor, irreversible)
-
FGFR2, FGFR1, FGFR3
- G
- G007-LK (TNKS1/2 inhibitor)
-
APC+PIK3CA
- Garsorasib (KRAS G12C inhibitor)
-
KRAS
- GB263T (trispecific EGFR/cMET/cMET antibody)
-
EGFR, MET
- GDC-0077 (PI3K alpha inhibitor)
-
PIK3CA
- GDC0623
-
BRAF
- GDC6036
-
HRAS, NRAS
- Gedatolisib + Fulvestrant
-
ERBB2 (HER2)+ESR1 (ER)+PIK3CA
- Gedatolisib + Fulvestrant + Palbociclib
-
ERBB2 (HER2)+ESR1 (ER)+PIK3CA
- Gedatolisib + Palbociclib + Fulvestrant
-
ERBB2 (HER2)+ESR1 (ER)
- Gedatolisib + Palbociclib + Letrozole
-
ERBB2 (HER2)+ESR1 (ER)
- Gefitinib (EGFR inhibitor, first generation)
-
EGFR, EGFR+ERBB2 (HER2), ERBB2 (HER2), BCL2L11, CRKL, EGFR+ALK, EGFR+RB1, EGFR+RET, EGFR+ROS1, EGFR+TP53, FBXW7, FGFR2, FGFR3, MET
- Gefitinib + Capmatinib
-
EGFR+MET
- Gefitinib + Gemcitabine
-
EGFR+ERRFI1
- Gemtuzumab Ozogamicin (anti-CD33 antibody-drug conjugate)
-
CD33
- GFH375 (KRAS G12D inhibitor)
-
KRAS
- GGTI-2418 (geranylgeranyl transferase inhibitor)
-
KRAS
- Gilteritinib (AXL/FLT3 inhibitor)
-
FLT3, LTK, ABL1, NRAS
- Giredestrant (selective estrogen receptor degrader)
-
ESR1 (ER)
- Giredestrant + Everolimus
-
ERBB2 (HER2)+ESR1 (ER)
- Glecirasib + JAB-3312
-
KRAS
- Glesatinib (MET inhibitor, type 2)
-
MET
- GnRH agonist
-
AR, AURKA, ESR1 (ER), MYCN, RB1, TP53
- Goserelin (GnRH analogue)
-
ESR1 (ER), PGR
- GQ1001 (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- GSK126 (EZH2 inhibitor)
-
ARID1A, EZH2, SMARCA4
- GSK343 (EZH2 inhibitor)
-
H3F3A, KDM6A
- GSK2256098 (FAK inhibitor)
-
NF2
- GSK2636771 (PI3K beta inhibitor)
-
PTEN
- GSK2849330 (anti-ERBB3 monoclonal antibody)
-
ERBB3, NRG1
- GSK3368715 (type 1 PRMT inhibitor)
-
MTAP
- GSK_WRN4 (WRN inhibitor)
-
Microsatellite Instability (MSI)
- Gunagratinib (pan-FGFR inhibitor, pan-FGFR inhibitor, irreversible)
-
FGFR2
- GV1001 + Gemcitabine + Capecitabine
-
CCL11
- H
- H3B-6545 (selective estrogen receptor covalent antagonist)
-
ESR1 (ER)
- H3B-8800 (SF3B1 inhibitor)
-
SF3B1, SRSF2
- H3Mab-17 (anti-ERBB3 monoclonal antibody)
-
ERBB3
- H231 (anti-EREG antibody-drug conjugate)
-
KRAS+NRAS
- Halofuginone (glutamyl-prolyl tRNA synthetase inhibitor)
-
MYCN
- HB-201 (vaccine therapy, HPV-E6/HPV-E7-targeting)
-
HPV genotype
- HB-201 + HB-202
-
HPV genotype
- HMBD-001 (anti-ERBB3 monoclonal antibody, third generation)
-
ERBB3, TP63
- HRO761 (WRN inhibitor)
-
Microsatellite Instability (MSI)
- HRS-1167 (PARP1-selective inhibitor)
-
BRCA1, BRCA2, PALB2, RAD51C, RAD51D
- HRS-4642
-
KRAS
- HRS-7058
-
KRAS
- I
- IAG933 (YAP-TEAD inhibitor)
-
NF2
- IBI334 (bispecific EGFR/B7H3 antibody)
-
EGFR
- IBI351 (KRAS G12C inhibitor)
-
KRAS
- IBI3001 (bispecific EGFR/B7H3 antibody-drug conjugate)
-
CD276 (B7-H3), EGFR
- Ibrutinib (BTK inhibitor)
-
CD20, MYD88, TP53, CXCR4
- Ibrutinib + Rituximab
-
CD20
- Icotinib (EGFR inhibitor, first generation)
-
EGFR
- ICP-723 (TRK inhibitor, second generation)
-
NTRK1, NTRK2, NTRK3
- Idarubicin + Cytarabine
-
U2AF1
- IDRX-42
-
KIT (CD117), PDGFRA
- II-B08 (PTP inhibitor)
-
NRAS
- IK-930 (YAP-TEAD inhibitor)
-
NF2, WWTR1, YAP1
- Imatinib (BCR-ABL1 inhibitor, first generation, KIT inhibitor, PDGFRA inhibitor)
-
ABL1, KIT (CD117), PDGFB, PDGFRA, PDGFRB, CSF1, CTNNB1+KIT, LZTR1, NF1, NF1+KIT, NRAS, PTPN11, WT1
- Imatinib + Binimetinib
-
KIT (CD117)
- Imatinib + Hydroxyurea
-
KIT (CD117)
- IMC-F106C (bispecific T-cell engager, PRAME-targeting)
-
HLA-A2+PRAME
- IMGN632
-
IL3RA
- Imlunestrant (selective estrogen receptor degrader)
-
ESR1 (ER)+ERBB2 (HER2), ESR1 (ER)
- Imlunestrant + Abemaciclib
-
ESR1 (ER)+ERBB2 (HER2)
- immune checkpoint blockade,CTLA-4 targeting
-
Microsatellite Instability (MSI), Mismatch repair (MMR)
- immune checkpoint blockade,PD-1 targeting
-
Microsatellite Instability (MSI), Mismatch repair (MMR), Tumour Mutational Burden (TMB)
- immune checkpoint blockade,PD-L1 targeting
-
Microsatellite Instability (MSI), Mismatch repair (MMR), Tumour Mutational Burden (TMB)
- immune checkpoint blockade,PD-L1-targeting
-
CD274 (PD-L1)
- IMU-131 (ERBB2 B-cell antigen)
-
ERBB2 (HER2)
- Inavolisib (PI3K alpha inhibitor)
-
ESR1 (ER)+ERBB2 (HER2)+PIK3CA, PIK3CA
- INCB161734 (KRAS G12D inhibitor)
-
KRAS
- Infigratinib (FGFR1/2/3 inhibitor, FGFR1/2/3 inhibitor, reversible)
-
FGFR2, FGFR3, FGFR1, MET
- INX-315 (CDK2 inhibitor)
-
ESR1 (ER), ESR1 (ER)+CCNE1
- Ipatasertib (pan-AKT inhibitor)
-
AKT1, PIK3CA, PIK3R1, PTEN
- Ipatasertib + Abiraterone
-
PTEN
- Ipatasertib + FOLFOX
-
PIK3CA, PTEN
- Ipatasertib + Paclitaxel
-
AKT1, PIK3CA, PTEN
- Ipilimumab + Nivolumab
-
Microsatellite Instability (MSI), Mismatch repair (MMR), POLD1, POLE, ATM, BRCA2, CDK12, Tumour Mutational Burden+Microsatellite Instability, Tumour Mutational Burden+Mismatch repair
- Ipilimumab + Nivolumab + Carboplatin + Paclitaxel
-
Tumour Mutational Burden (TMB)
- Ipilimumab + Nivolumab + Carboplatin + Pemetrexed
-
Tumour Mutational Burden (TMB)
- Ipilimumab + Nivolumab + Cisplatin + Pemetrexed
-
Tumour Mutational Burden (TMB)
- Irinotecan + Cetuximab
-
NRAS
- Isatuximab-irfc + Pomalidomide + Dexamethasone
-
CD38
- Isotretinoin + Navitoclax
-
MYC, MYCN
- Itraconazole (SMO inhibitor)
-
PTCH1, SMO
- Ivosidenib (IDH1 R132 inhibitor)
-
IDH1, BRAF, FLT3, IDH2, KIT (CD117), KRAS, NF1, NRAS, PTPN11
- Ivosidenib + Azacitidine
-
IDH1
- Izalontamab brengitecan (bispecific EGFR/ERBB3 antibody)
-
EGFR, EGFR+ERBB3, ERBB2 (HER2), KRAS, MET, ALK, RET, ROS1
- J
- JAB-21822 (KRAS G12C inhibitor)
-
KRAS
- JQ1 (BET inhibitor)
-
ARID1A, EIF1AX, EIF1AX+NRAS, KDM6A, SMO, SUZ12
- JQD443
-
HRAS, NRAS
- JSKN003 (biparatopic ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- L
- Lanreotide (somatostatin analog)
-
SSTR2
- Lapatinib (ERBB2 inhibitor, first generation, EGFR inhibitor, type II)
-
EGFR, ERBB2 (HER2), ERBB3, PTEN
- Lapatinib + Afatinib
-
ERBB4
- Lapatinib + Capecitabine
-
ERBB2 (HER2)
- Lapatinib + Letrozole
-
ERBB2 (HER2)
- Lapatinib + Paclitaxel
-
ERBB2 (HER2)
- Lapatinib + Trastuzumab
-
ERBB2 (HER2), ERBB3, BRAF
- Larotrectinib (TRK inhibitor, first generation)
-
NTRK1, NTRK2, NTRK3, BRAF, CDKN2A, EGFR
- Larotrectinib, Selitrectinib, Zurletrectinib, Repotrectinib
-
NTRK2
- Lasofoxifene + Abemaciclib
-
ESR1 (ER)
- Lazertinib (EGFR inhibitor, third generation)
-
EGFR
- Lazertinib (EGFR inhibitor, third generation)
-
EGFR
- Lenalidomide + Rituximab
-
CD20
- Lenvatinib (VEGF inhibitor)
-
RET, SSTR2
- Lenvatinib + Pembrolizumab
-
Microsatellite instability+Mismatch repair, Mismatch repair (MMR)
- Letetresgene autoleucel
-
CTAG1B
- Letrozole (aromatase inhibitor)
-
ESR1 (ER), PGR
- Letrozole + Palbociclib
-
ESR1 (ER)
- Lifirafenib (EGFR/RAF dimer inhibitor)
-
BRAF, KRAS
- Lifirafenib + Mirdametinib
-
KRAS, BRAF, NRAS
- Linsitinib + Erlotinib
-
EGFR
- Lirafugratinib (FGFR2 inhibitor)
-
FGFR2
- LOP628 (anti-cKIT antibody-drug conjugate)
-
KIT (CD117)
- Loratinib
-
ROS1
- Lorlatinib (ALK inhibitor, third generation, ROS1 inhibitor)
-
ALK, ROS1, LTK
- LOXO-783 (PI3Kalpha H1047R inhibitor)
-
PIK3CA
- LOXO-783 + Anaztrozole
-
PIK3CA
- LOXO-783 + Fulvestrant
-
PIK3CA
- LOXO-783 + Letrozole
-
PIK3CA
- LOXO-783 + Paclitaxel
-
PIK3CA
- LTT462 (ERK inhibitor)
-
HRAS, KRAS, NRAS, PTPN11
- Lu-177 vipivotide tetraxetan (radioconjugate, PSMA-targeting)
-
PSMA
- Lucitanib (VEGFR/PDGFR/FGFR1/2/3 inhibitor)
-
FGFR1
- Lumretuzumab (anti-ERBB3 monoclonal antibody)
-
NRG1
- Lumretuzumab + Erlotinib
-
NRG1
- Luveltamab tazevibulin (anti-FR-alpha antibody-drug conjugate)
-
FOLR1 (Folate receptor alpha)
- LY2874455 (pan-FGFR inhibitor, pan-FGFR inhibitor, reversible)
-
FRS2
- LY3009120 (RAF inhibitor, type 2)
-
BRAF, RAF1
- LY3023414 (PI3K/mTOR inhibitor)
-
AKT1, PIK3CA, PIK3R1, PTEN
- LY3143921 (CDC7 inhibitor)
-
TP53
- LY3214996 (ERK inhibitor)
-
BRAF, HRAS, KRAS, NRAS, PTPN11
- LY3214996 + Abemaciclib
-
BRAF
- LY3295668 (AURKA inhibitor)
-
MYCN, RB1
- LY3410738 (IDH1 R132 inhibitor, covalent)
-
IDH1, IDH2
- LY3537982 (KRAS G12C inhibitor)
-
KRAS
- LY4170156 (anti-FR-alpha antibody-drug conjugate)
-
FOLR1 (Folate receptor alpha)
- M
- M6620 (ATR inhibitor)
-
ARID1A
- M94140
-
CEACAM5
- Margetuximab (anti-ERBB2 monoclonal antibody)
-
ERBB2 (HER2)
- Margetuximab + Capecitabine
-
ERBB2 (HER2)
- Margetuximab + Eribulin
-
ERBB2 (HER2)
- Margetuximab + Gemcitabine
-
ERBB2 (HER2)
- Margetuximab + Pembrolizumab
-
ERBB2 (HER2)
- Margetuximab + Vinorelbine
-
ERBB2 (HER2)
- MDM2 inhibitor
-
TP53
- MDNA11 (IL-2 superkine)
-
Microsatellite Instability (MSI)
- MEDI7247 (anti-ASCT2 antibody-drug conjugate)
-
SLC1A5
- Medroxyprogesterone Acetate (synthetic progestin)
-
ESR1 (ER), PGR
- MEK inhibitor
-
HGF, KRAS
- MEK inhibitor + anti-EGFR monoclonal antibody
-
BRAF
- MEK inhibitor + SHP2 inhibitor
-
KRAS
- Methotrexate (antifolate, antimetabolite)
-
DHFR
- MGC018 (anti-B7H3 antibody-drug conjugate)
-
CD276 (B7-H3)
- Midostaurin (FLT3 inhibitor, KIT inhibitor, ATP-competitive, PDGFR inhibitor, PKC inhibitor, VEGFR2 inhibitor)
-
FLT3, KIT (CD117), PDGFRA
- MIL93 (anti-CLDN18.2 monoclonal antibody)
-
CLDN18
- Milademetan Tosylate (MDM2 inhibitor)
-
MDM2
- Mirdametinib (MEK inhibitor)
-
NF1, KRAS
- Mirdametinib + JQ1
-
NF1+SUZ12
- Mirvetuximab soravtansine (anti-FR-alpha antibody-drug conjugate)
-
FOLR1 (Folate receptor alpha)
- Mirvetuximab soravtansine + Bevacizumab
-
FOLR1 (Folate receptor alpha)
- Mivebresib (BET inhibitor)
-
AR, MYC, MYCN, MYCL
- MK-1084 (KRAS G12C inhibitor)
-
KRAS
- MK-1084 + Cetuximab
-
KRAS
- MK-2206
-
PIK3R1
- MK-2206 + Gemcitabine
-
EGFR+ERRFI1
- MK2206 (AKT inhibitor)
-
PIK3CA, PTEN
- Mobocertinib (EGFR inhibitor, exon 20 selective, ERBB2 inhibitor, exon 20 selective)
-
EGFR
- Mogamulizumab (anti-CCR4 monoclonal antibody)
-
CCR4
- Molibresib (BET inhibitor)
-
ARID1A
- MOMA-341 (WRN inhibitor)
-
Microsatellite Instability (MSI), Mismatch repair (MMR)
- MORAb-202 (anti-FR-alpha antibody-drug conjugate)
-
FOLR1 (Folate receptor alpha)
- MRG004A
-
F3
- MRK003 (gamma secretase inhibitor)
-
NOTCH1, NOTCH2, NOTCH3
- mRNA-5671 (mRNA personalised cancer vaccine, KRAS-targeting)
-
KRAS
- MRTX1133 (KRAS G12D inhibitor)
-
KRAS
- MRTX1719 (PRMT5 inhibitor, MTA-co-operative)
-
MTAP
- MT-303 (GPC3-targeting lipid-nanoparticle CAR mRNA, GPC3-targeting lipid-nanoparticles)
-
GPC3
- MT-5111 (anti-ERBB2 engineered toxin body)
-
ERBB2 (HER2)
- MTYX-5000
-
MET
- MVC-101 (bispecific T-cell engager, EGFR-targeting)
-
EGFR
- MYTX-011 (anti-cMET antibody-drug conjugate)
-
MET
- N
- Nab-sirolimus (mTOR inhibitor)
-
TSC2, TSC1
- Naporafenib (RAF dimer inhibitor)
-
BRAF
- Naporafenib + Trametinib
-
NRAS
- Naporfenib
-
BRAF
- Navtemadlin (MDM2 inhibitor)
-
TP53, MDM2+TP53+IDH1
- Nazartinib (EGFR inhibitor, third generation)
-
EGFR
- NB003
-
KIT (CD117), PDGFRA
- Neladalkib (ALK inhibitor, fourth generation)
-
ALK
- Neratinib (EGFR inhibitor, second generation, ERBB2 inhibitor, second generation, ERBB3 inhibitor)
-
ERBB2 (HER2), EGFR, ERBB4, ERBB2 (HER2)+ERBB3, ERBB3
- Neratinib + Alpelisib
-
ERBB2 (HER2)+ERBB3
- Neratinib + Capecitabine
-
ERBB2 (HER2)
- Neratinib + Trastuzumab emtansine
-
ERBB2 (HER2)
- Nilotinib (BCR-ABL1 inhibitor, second generation, KIT inhibitor, PDGFR inhibitor)
-
ABL1, CSF1, KIT (CD117), BAP1, NF1, PDGFRA, PTPN11, WT1
- Nimotuzumab + Gemcitabine
-
KRAS
- Nintedanib (PDGFRA/VEGFR/FGFR1/2/3 inhibitor)
-
KIT (CD117), PDGFRA
- Niraparib (PARP inhibitor)
-
BRCA1, BRCA2, Homologous Recombination Deficiency Score (HRD), BAP1, RAD51C
- Niraparib + Abiraterone Acetate
-
BRCA1, BRCA2
- Niraparib + Radiotherapy
-
MGMT
- Nirogacestat (gamma secretase inhibitor)
-
APC, CTNNB1, NOTCH1
- Nivolumab (anti-PD-1 monoclonal antibody)
-
Microsatellite Instability (MSI), Mismatch repair (MMR), MLH1, MSH2, POLD1, POLE, ARID1A, ARID1B, CD274 (PD-L1), CDK12, CXCL13, PBRM1, PMS2, SMARCA4, SMARCB1, Tumour Mutational Burden (TMB), ALK, EGFR, HLA-A
- Nivolumab + CAPOX
-
CD274 (PD-L1)
- Nivolumab + FLOX
-
Microsatellite instability+Mismatch repair
- Nivolumab + Fluorouracil + Cisplatin
-
CD274 (PD-L1)
- Nivolumab + FOLFOX
-
CD274 (PD-L1)
- Nivolumab + Ipilimumab
-
CD274+EGFR+ALK, Microsatellite Instability (MSI), Mismatch repair (MMR), Tumour Mutational Burden (TMB), CD274 (PD-L1), CDK12
- NST-628 (pan-RAF/MEK glue)
-
BRAF, KRAS, NRAS
- NVL-520 (ROS1 inhibitor)
-
ROS1
- O
- OBI-999 (anti-globoH antibody-drug conjugate)
-
Globo H
- Obinutuzumab (anti-CD20 monoclonal antibody)
-
CD20
- Obrixtamig (bispecific T-cell engager, DLL3-targeting)
-
DLL3
- Octreotide (somatostatin analog)
-
SSTR2
- Odronextamab (bispecific T-cell engager, CD20-targeting)
-
CD20
- Ofatumumab (anti-CD20 monoclonal antibody)
-
CD20
- Olaparib (PARP inhibitor)
-
BRCA1, BRCA2, IDH1, IDH2, PALB2, ARID1A, ARID2, ATM, ATRX, BARD1, BRCA2+PTEN, BRIP1, CDK12, CHEK1, CHEK2, FAM175A, FANCC, FANCG, FANCI, FANCL, FLCN, Homologous Recombination Deficiency Score (HRD), KMT2C, MRE11A, Mutational signature, NBN, PBRM1, PPM1D, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, SLX4, SRSF2, U2AF1, XRCC2, BAP1, BRCA1+ERBB2 (HER2), FANCD2, PAXIP1, PPP2R2A, PTEN, RIF1, TP53BP1
- Olaparib + Bevacizumab
-
BRCA1, BRCA2, Homologous Recombination Deficiency Score (HRD)
- Olaparib + Ceralasertib
-
ATM, BRCA1, BRCA2, CCNE1, RAD51
- Olaparib + Durvalumab
-
ATM, BRCA2, BRCA1
- Olaparib + Temozolomide
-
RAD51, MYC, MYCL, MYCN
- Olaratumab (anti-PDGFRA monoclonal antibody)
-
PDGFRA
- Olaratumab + Doxorubicin
-
PDGFRA
- Olomorasib (KRAS G12C inhibitor)
-
KRAS
- Olomorasib + Cetuximab
-
KRAS
- Olutasidenib (IDH1 R132 inhibitor)
-
IDH1
- Onapristone (progesterone antagonist)
-
PGR
- ONC201 (DRD2 antagonist, AKT inhibitor, ERK inhibitor)
-
TP53
- ONC201 + Paxalisib
-
H3F3A
- Onvansertib (PLK1 inhibitor)
-
KRAS
- Onvansertib + FOLFIRI + Bevacizumab
-
KRAS
- Osimertinib (EGFR inhibitor, third generation)
-
EGFR, EGFR+ERBB2 (HER2), ERBB2 (HER2), ALK, BRAF, EGFR+ALK, EGFR+BRAF, EGFR+EGFR, EGFR+RB1, EGFR+RET, EGFR+ROS1, EGFR+TP53, FGFR2, FGFR3, GNAS, KRAS, MET, PIK3CA, RBM10, RET
- Osimertinib + Alectinib
-
EGFR+ALK
- Osimertinib + Crizotinib
-
EGFR+ALK, EGFR+MET, EGFR+ROS1
- Osimertinib + Gefitinib
-
EGFR
- Osimertinib + Navitoclax
-
EGFR+RBM10
- Osimertinib + Necitumumab
-
EGFR
- Osimertinib + Pemetrexed
-
EGFR
- Osimertinib + Pralsetinib
-
EGFR+RET
- Osimertinib + Savolitinib
-
EGFR+MET
- Osimertinib + Tepotinib
-
EGFR+MET, EGFR+MET+ALK, EGFR+MET+BRAF, EGFR+MET+KRAS
- Osimertinib + Trastuzumab Emtansine
-
EGFR+ERBB2 (HER2)
- Oxaliplatin (platinum-based antineoplastic agent)
-
BRCA1, BRCA2
- P
- Paclitaxel (taxane)
-
LGALS1
- Palacaparib (PARP1-selective inhibitor)
-
BRCA1, BRCA2
- Palazestrant (complete estrogen receptor antagonist)
-
ESR1 (ER)
- Palbociclib (CDK4/6 inhibitor)
-
CDK4, GNAS, CDKN2A, ESR1 (ER), SMARCA4, WT1, CCND1, CCND2, CCND3, CCNE1, CDK6, ESR1 (ER)+MDM2, ESR1 (ER)+TP53, FAT1, RB1
- Palbociclib + Avelumab
-
CDK4, CDKN2A
- Palbociclib + Fulvestrant
-
ESR1 (ER)+ERBB2 (HER2)
- Palbociclib + Letrozole
-
ERBB2 (HER2)+ESR1 (ER), ESR1 (ER)
- Pamiparib (PARP inhibitor)
-
BRCA1, BRCA2
- Pamiparib + AZD7762
-
H3F3A
- Pamiparib + Tislelizumab
-
BRCA1, BRCA2
- Panitumumab (anti-EGFR monoclonal antibody)
-
KRAS+NRAS, BRAF, EGFR, KRAS, NRAS, ERBB2 (HER2), HRAS, MAP2K1, MET
- Panitumumab + Dabrafenib + Trametinib
-
BRAF
- Panitumumab + Fluorouracil
-
KRAS+NRAS
- Panitumumab + FOLFOX
-
ALK, BRAF, EGFR, ERBB3, KRAS, NRAS
- Panobinostat (pan-HDAC inhibitor)
-
BAP1
- PARP inhibitor
-
BAP1, BARD1
- Patritumab (anti-ERBB3 monoclonal antibody)
-
ERBB3
- Patritumab deruxtecan (anti-ERBB3 antibody-drug conjugate)
-
EGFR, ERBB2 (HER2), ERBB3, TOP1
- Pazopanib (KIT inhibitor, ATP-competitive, PDGFR inhibitor, VEGFR inhibitor)
-
KIT (CD117)
- PC14586 (mutant p53 reactivator, Y220C-selective)
-
TP53
- PD0325901 (MEK inhibitor)
-
BRAF, HRAS
- PD173074 (FGFR1 inhibitor)
-
FGFR1
- PDD00017273 (PARG inhibitor)
-
BARD1, BRCA1, BRCA2, FAM175A, MRE11A
- PDS0101 + M9241 + Bintrafusp alpha
-
HPV genotype
- Pelitinib
-
ERBB2 (HER2)
- Pembrolizumab (anti-PD-1 monoclonal antibody)
-
CD274 (PD-L1), Microsatellite Instability (MSI), Mismatch repair (MMR), Tumour Mutational Burden (TMB), POLD1, POLE, ARID1A, ARID1B, CD8, CDK12, PBRM1, SMARCA4, SMARCB1, ALK, B2M, EGFR, EGFR+CD274, FBXW7, JAK1, JAK2, KRAS+Microsatellite Instability, KRAS+Mismatch repair
- Pembrolizumab + Capecitabine + Oxaliplatin
-
ERBB2 (HER2)+CD274
- Pembrolizumab + Carboplatin + Gemcitabine
-
CD274 (PD-L1), Tumour Mutational Burden (TMB)
- Pembrolizumab + Carboplatin + Paclitaxel
-
CD274 (PD-L1)
- Pembrolizumab + Carboplatin + Paclitaxel + Bevacizumab
-
CD274 (PD-L1)
- Pembrolizumab + Carboplatin + Pemetrexed
-
NRG1
- Pembrolizumab + Cisplatin + Fluorouracil
-
CD274 (PD-L1)
- Pembrolizumab + Cisplatin + Gemcitabine
-
CD274 (PD-L1), Tumour Mutational Burden (TMB)
- Pembrolizumab + Cisplatin + Paclitaxel
-
CD274 (PD-L1)
- Pembrolizumab + Cisplatin + Paclitaxel + Bevacizumab
-
CD274 (PD-L1)
- Pembrolizumab + Fluorouracil + Cisplatin
-
ERBB2 (HER2)+CD274
- Pembrolizumab + Nab-paclitaxel
-
CD274 (PD-L1)
- Pembrolizumab + Paclitaxel
-
CD274 (PD-L1)
- Pembrolizumab + Trastuzumab + Capecitabine + Oxaliplatin
-
ERBB2 (HER2)
- Pembrolizumab + Trastuzumab + Cisplatin + Fluorouracil
-
ERBB2 (HER2)
- Pembrolizumab + Trastuzumab + Oxaliplatin + Capecitabine
-
ERBB2 (HER2)
- Pembrolizumab + Vibostolimab
-
CD274 (PD-L1)
- Pemigatinib (FGFR1/2/3 inhibitor, FGFR1/2/3 inhibitor, reversible)
-
FGFR2, FGFR1, FGFR2 , FGFR3, BRAF, KRAS, NRAS
- Pertuzumab (anti-ERBB2 monoclonal antibody, dimerization inhibitor)
-
ERBB2 (HER2)
- Pertuzumab + Trastuzumab
-
ERBB2 (HER2)
- Pexidartinib (CSF1R inhibitor, FLT3 inhibitor, KIT inhibitor)
-
CSF1
- PF-07104091
-
ERBB2 (HER2)+ESR1 (ER)
- PF-07220060 (CDK4 selective inhibitor)
-
ERBB2 (HER2)+ESR1 (ER)
- PF-07248144 (KAT6 inhibitor)
-
ERBB2 (HER2)+ESR1 (ER)
- PF-07709933
-
BRAF
- PF-9363 (KAT6 inhibitor)
-
ESR1 (ER)+ERBB2 (HER2), KAT6A
- Pictilisib (pan-PI3K inhibitor)
-
ERBB3
- Pictilisib + Fulvestrant
-
PIK3CA
- Pictilisib + Paclitaxel
-
PIK3CA
- Pimitespib (HSP90 inhibitor)
-
KIT (CD117), PDGFRA
- Platinum-based antineoplastic agent
-
EMSY, ERCC1, ERCC2
- Plixorafenib (RAF dimer inhibitor)
-
BRAF
- PLX2853 (BET inhibitor)
-
ARID1A
- PLX2853 + carboplatin
-
ARID1A
- PLX4720 (RAF inhibitor)
-
RAF1
- Polatuzumab vedotin + Bendamustine + Rituximab
-
CD79B, KLHL6
- Ponatinib (BCR-ABL1 inhibitor, third generation, FGFR inhibitor, type 2, FLT3 inhibitor, TIE2 inhibitor, VEGFR inhibitor)
-
ABL1, FGFR3, RET, BAP1, FGFR1, FGFR2, LZTR1, NF1, PTPN11, WT1
- Ponatinib + Asciminib
-
ABL1
- Posaconazole (azole antifungal)
-
SMO
- Poziotinib (ERBB2 inhibitor, exon 20 selective)
-
EGFR, ERBB2 (HER2)
- Pralsetinib (RET-selective inhibitor)
-
RET, KRAS, MET
- PRN1371 (pan-FGFR inhibitor, irreversible, pan-FGFR inhibitor)
-
FGF19
- Proxalutamide (antiandrogen, nonsteroidal, second generation)
-
AR
- PRT811 (PRMT5 inhibitor)
-
IDH1
- PRT3789 (SMARCA2 degrader)
-
SMARCA4
- PRT7732 (SMARCA2 degrader)
-
SMARCA4
- Puxitatug samrotecan (anti-B7H4 antibody-drug conjugate)
-
VCTN1 (B7-H4)
- Pyrotinib (EGFR inhibitor, exon 20 selective, ERBB2 inhibitor, second generation)
-
ERBB2 (HER2), EGFR
- Pyrotinib + Capecitabine
-
ERBB2 (HER2)
- Pyrotinib + Irinotecan
-
ERBB3
- Q
- Quarfloxin (RNA polymerase I transcription inhibitor)
-
MYCN
- Quizartinib (FLT3 inhibitor, KIT inhibitor)
-
FLT3
- R
- RAF709 + Trametinib
-
KRAS
- RAF dimer inhibitor
-
BRAF
- Ravoxertinib (ERK inhibitor)
-
BRAF, HRAS, KRAS, NRAS, PTPN11
- RC48-ADC (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- Regorafenib (KIT/PDGFR/RET/VEGFR/FGFR inhibitor)
-
KIT (CD117), PDGFRA, BRAF, FBXW7, RET
- Regorafenib + ABT-737
-
FBXW7
- Repotrectinib (ALK inhibitor, third generation, ROS1 inhibitor, TRK inhibitor, second generation)
-
ROS1, NTRK1, NTRK2, NTRK3, ALK, LTK
- Revumenib (menin-MLL1 inhibitor)
-
KMT2A
- Ribociclib (CDK4/6 inhibitor)
-
CCND1, CDK4, H3F3A, CCND3, CCNE1, CDK6, CDKN2A, ESR1 (ER)+MDM2, ESR1 (ER)+TP53, FAT1, RB1, SPEN
- Ribociclib + Anastrozole
-
Intrinsic subtype, ESR1 (ER)
- Ribociclib + Anastrozole + Goserelin
-
ESR1 (ER)
- Ribociclib + Binimetinib
-
NRAS
- Ribociclib + Fulvestrant
-
ESR1 (ER)+ERBB2 (HER2), Intrinsic subtype
- Ribociclib + Letrozole
-
ERBB2 (HER2)+ESR1 (ER), Intrinsic subtype, ESR1 (ER)
- Ribociclib + Letrozole + Goserelin
-
ESR1 (ER)
- Ribociclib + Tamoxifen
-
Intrinsic subtype, ESR1 (ER)
- Ribociclib + Tamoxifen + Goserelin
-
ESR1 (ER)
- Ripretinib (KIT inhibitor, switch control kinase inhibitor, PDGFRA inhibitor)
-
KIT (CD117), PDGFRA
- Rituximab (anti-CD20 monoclonal antibody)
-
CD20
- RK-582 (TNKS1/2 inhibitor)
-
APC+PIK3CA
- RLY-2608 (PI3K alpha inhibitor, allosteric, mutant-selective)
-
PIK3CA
- RM-018
-
HRAS, NRAS
- RMC-4550 (SHP2 inhibitor)
-
BRAF, KRAS, NF1, NRAS, PTPN11, RAC1, RAF1
- RMC-5552 + RMC-6272
-
KRAS
- RMC-6236
-
KRAS
- RMC-9805
-
KRAS
- RO7428731 (bispecific T-cell engager, EGFRvIII-targeting)
-
EGFR
- Rogaratinib (FGFR1/2/3 inhibitor, reversible, pan-FGFR inhibitor)
-
FGFR1, FGFR3, FGFR2, MET
- ROS1 inhibitor
-
ROS1
- RP-6306 (PKMYT1 inhibitor)
-
CCNE1
- Rucaparib (PARP inhibitor)
-
BRCA1, BRCA2, Homologous Recombination Deficiency Score (HRD), Loss-of-heterozygosity score, BAP1, PALB2, ARID1A, ARID2, BRIP1, CDK12, FANCA, PBRM1, RAD50, RAD51C, ATM
- Rucaparib + MK-1775
-
BRCA1+BRCA2
- Rucaparib + PF-477736
-
BRCA1+BRCA2
- Rucaparib + VE-821
-
BRCA1+BRCA2
- Runimotamab (bispecific T-cell engager, ERBB2-targeting)
-
ERBB2 (HER2)
- Ruxolitinib (JAK1/JAK2 inhibitor)
-
JAK2, JAK1
- RXC004 (PORCN inhibitor)
-
RNF43, RSPO1
- S
- S63845 (MCL1 inhibitor)
-
BCL2L1
- Sacituzumab Govitecan (anti-Trop2 antibody-drug conjugate)
-
ESR1 (ER)+ERBB2 (HER2), TACSTD2 (Trop2), TOP1
- Sacituzumab govitecan (anti-Trop2 antibody-drug conjugate)
-
ESR1 (ER)+ERBB2 (HER2)
- Sacituzumab tirumotecan (anti-Trop2 antibody-drug conjugate)
-
EGFR, ESR1 (ER)+ERBB2 (HER2)
- Sacituzumab tirumotecan (anti-Trop2 antibody-drug conjugate)
-
ESR1 (ER)+ERBB2 (HER2)
- Samuraciclib + Fulvestrant
-
ESR1 (ER)
- Sapanisertib (mTORC1/mTORC2 inhibitor)
-
RICTOR
- Sapanisertib + Metformin
-
AKT1, AKT2, MTORC1, PIK3CA, PTEN
- SAR405838 (p53-HDM2 interaction inhibitor, MDM2 inhibitor)
-
TP53
- Savolitinib (MET inhibitor, type 1)
-
MET
- Savolitinib + Osimertinib
-
EGFR+MET
- SCH772984 (ERK inhibitor)
-
BRAF, KRAS, NRAS
- Selinexor (XPO1 inhibitor)
-
CALB1, XPO1
- Selinexor + Docetaxel
-
KRAS+TP53
- Selitrectinib (TRK inhibitor, second generation)
-
NTRK1, NTRK2, NTRK3
- Selitrectinib, Zurletrectinib
-
NTRK1
- Selpercatinib (RET-selective inhibitor)
-
RET, BRAF, FGFR1, KRAS, MET
- Selumetinib (MEK inhibitor)
-
NF1, BRAF, HRAS, MAP2K1, MAP2K4, MAP3K1, KRAS, NRAS
- Selumetinib + Docetaxel
-
KRAS
- Selumetinib + Irinotecan
-
KRAS
- Serclutamab Talirine (anti-EGFR/PBD antibody-drug conjugate)
-
EGFR
- Seribantumab (anti-ERBB3 monoclonal antibody)
-
NRG1
- Seribantumab + Docetaxel
-
NRG1
- Sevabertinib (EGFR/ERBB2 inhibitor, mutant-selective, non-covalent)
-
ERBB2 (HER2), EGFR
- SGN-PDL1V (anti-PD-L1 antibody-drug conjugate)
-
CD274 (PD-L1)
- SHP099 (SHP2 inhibitor)
-
BRAF, NF1, KRAS, NRAS, PTPN11
- SHP099 + Trametinib
-
BRAF, KRAS, NRAS
- SHP099 + Ulixertinib
-
NRAS
- SHP2 inhibitor
-
KRAS
- SHR-1826 (anti-cMET antibody-drug conjugate)
-
MET
- SHR-A1811 (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- SHR-A1904 (anti-CLDN18.2 antibody-drug conjugate)
-
CLDN18
- Sirolimus (mTORC1/mTORC2 inhibitor)
-
FLCN, TSC2
- SM08502 (CLK inhibitor)
-
APC
- SN-38 + VE-822
-
ATR
- SNS-032 (CDK2 inhibitor)
-
CCNE1
- SNV1521 (PARP1-selective inhibitor)
-
BRCA2, PALB2, RAD51D
- Sonidegib (SMO inhibitor, first generation)
-
PTCH1, BRAF, HRAS, SMO
- Sorafenib (CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor, CRAF inhibitor, FLT3 inhibitor, KIT inhibitor, PDGFR inhibitor, VEGFR inhibitor)
-
FLT3, KIT (CD117), ARAF, BRAF, PDGFRA, RET
- Sotorasib (KRAS G12C inhibitor, KRAS G12C/NRAS G12C/HRAS G12C inhibitor)
-
KRAS, HRAS, KEAP1+KRAS, NRAS, BRAF, MRAS
- Sotorasib + Panitumumab
-
KRAS
- Sotorasib + Tipifarnib
-
KRAS
- SP2509 (LSD1 inhibitor)
-
DNMT3A
- SR-4835 (CDK12/CDK13 inhibitor)
-
CDK12
- STX-478 (PI3Kalpha inhibitor, mutant selective, kinase/helical domain)
-
PIK3CA
- Sunitinib (KIT inhibitor, first generation, PDGFR inhibitor, VEGFR inhibitor)
-
KIT (CD117), RET, SDHA, SDHB, PDGFRA, FGFR1, FGFR2, FLT3
- T
- T-025 (CLK inhibitor)
-
MYC
- Tafasitamab + Lenalidomide
-
CD19
- Tagraxofusp-erzs (IL-3 diphtheria toxin fusion protein)
-
CD123
- TAK632 (RAF inhibitor, type 2)
-
BRAF
- Taladegib (SMO inhibitor, second generation)
-
SMO
- Talazoparib (PARP inhibitor)
-
BRCA1, BRCA2, PALB2, ARID2, ATM, BARD1, CDK12, CHEK1, FANCC, FANCM, IDH1, IDH2, KEAP1, PBRM1, PTEN, RAD21, SF3B1, SMC3, SRSF2, STAG2, ATR, BAP1, BRIP1, CHEK2, RAD50
- Talazoparib + AZD0156
-
SF3B1
- Talazoparib + VX-970
-
TP53+RB1
- Taletrectinib (ROS1 inhibitor, TRK inhibitor, second generation)
-
ROS1, NTRK1, NTRK2, NTRK3
- Tamoxifen (selective estrogen receptor modulator)
-
ESR1 (ER), PGR, FGFR1
- Tamoxifen + Medroxyprogesterone Acetate
-
ESR1 (ER)
- Tarextumab (anti-notch receptor monoclonal antibody)
-
NOTCH3
- Tarlatamab (bispecific T-cell engager, DLL3-targeting)
-
DLL3
- Tarloxotinib (pan ERBB inhibitor, hypoxia activating)
-
ERBB2 (HER2), EGFR, NRG1, ERBB3
- TAS-102 + Olaparib
-
TP53
- TAS-102 + Talazoparib
-
TP53
- Taselisib (PI3K alpha inhibitor)
-
PIK3CA
- Taselisib + Fulvestrant
-
PIK3CA
- Tazemetostat (EZH2 inhibitor)
-
EZH2, SMARCB1, BAP1, SMARCA2, SMARCA2+SMARCA4, SMARCA4, RB1
- Tebentafusp (bispecfic T-cell engager, gp100-targeting)
-
HLA-A2, HLA-A+PMEL
- Tebentafusp + Durvalumab
-
HLA-A2
- Tebentafusp + Durvalumab + Tremelimumab
-
HLA-A2
- Telisotuzumab adizuteca
-
MET
- Telisotuzumab Vedotin (anti-cMET antibody-drug conjugate)
-
MET, EGFR+MET
- Temozolomide (alkylating agent)
-
MGMT
- Temozolomide + Ipilimumab + Nivolumab
-
MGMT
- Temsirolimus (mTORC1 inhibitor)
-
MTOR, TSC2
- Tepotinib (MET inhibitor, type 1)
-
MET
- Tepotinib + Cetuximab
-
MET
- Tepotinib + Gefitinib
-
EGFR+MET
- TetMYB (MYB-targeting vaccine)
-
MYB
- Tipifarnib (farnesyltransferase inhibitor)
-
HRAS
- TK216 + Vincristine
-
FLI1
- Topotecan (topoisomerase inhibitor)
-
MYC, MYCL, MYCN
- Toripalimab (anti-PD-1 monoclonal antibody)
-
CD274 (PD-L1), Tumour Mutational Burden (TMB)
- Tovorafenib (RAF inhibitor, type 2)
-
BRAF
- TPX-0046 (RET/SRC inhibitor, RET inhibitor)
-
RET
- TQB2102 (bispecific ERBB2/ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- Trabectedin (DNA minor groove-binding agent)
-
BRCA1, BRCA2
- Trametinib (MEK inhibitor)
-
BRAF, MAP2K1, CBL, KRAS, NRAS, PTPN11, EIF1AX, EIF1AX+NRAS, GNAS, LZTR1, NF1, NF1+SUZ12, RAF1, RASA1, GNA11, GNAQ, MAP2K2
- Trametinib (MEK inhibitor)
-
NF1, CAMTA1
- Trametinib + Hydroxychloroquine
-
KRAS
- Trametinib + Palbociclib
-
KRAS
- Trametinib + Ponatinib
-
KRAS
- Trametinib + RMC-4550
-
NF1
- Trametinib + SHP099
-
KRAS
- Trastuzumab (anti-ERBB2 monoclonal antibody)
-
ERBB2 (HER2), BRAF, EGFR, ERBB2 (HER2)+ERBB3, ERBB2 (HER2)+PTEN, ERBB3, KRAS, MET, PIK3CA, PTEN
- Trastuzumab + Capecitabine
-
ERBB2 (HER2)
- Trastuzumab + Capecitabine + Oxaliplatin
-
ERBB2 (HER2)
- Trastuzumab + Carboplatin
-
ERBB2 (HER2)
- Trastuzumab + Cisplatin + Capecitabine
-
ERBB2 (HER2)
- Trastuzumab + Cisplatin + Fluorouracil
-
ERBB2 (HER2)
- Trastuzumab + Docetaxel
-
ERBB2 (HER2)
- Trastuzumab + Lapatinib
-
ERBB2 (HER2), ERBB3
- Trastuzumab + Nivolumab
-
ERBB2 (HER2)
- Trastuzumab + Paclitaxel
-
ERBB2 (HER2)
- Trastuzumab + Pertuzumab
-
ERBB2 (HER2), BRAF, ERBB2 (HER2)+ERBB3, ERBB2 (HER2)+KRAS, ERBB3
- Trastuzumab + Pertuzumab + Docetaxel
-
ERBB2 (HER2)
- Trastuzumab + Pertuzumab + Paclitaxel
-
ERBB2 (HER2)
- Trastuzumab + Tucatinib
-
ERBB2 (HER2)
- Trastuzumab deruxtecan (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2), ESR1 (ER)+ERBB2 (HER2), ERBB2 (HER2)+KRAS, RB1
- Trastuzumab duocarmazine (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2)
- Trastuzumab Emtansine (anti-ERBB2 antibody-drug conjugate)
-
ERBB2 (HER2), ERBB2 (HER2)+KRAS
- Trastuzumab Emtansine + Pertuzumab
-
ERBB2 (HER2)
- Tremelimumab (anti-CTLA4 monoclonal antibody)
-
Tumour Mutational Burden (TMB)
- Trichostatin A (HDAC inhibitor)
-
KDM6A
- Tucatinib (ERBB2 inhibitor, third generation)
-
ERBB2 (HER2)
- Tucatinib + Trastuzumab
-
ERBB2 (HER2)
- Tucatinib + Trastuzumab Emtansine
-
ERBB2 (HER2)
- Tusamitamab ravtansine (anti-CEACAM5 antibody-drug conjugate)
-
CEACAM5
- Tuvusertib (ATR inhibitor)
-
ARID1A, ATRX, BRCA1, BRCA2, DAXX, TP53
- TYRA-300 (FGFR3 inhibitor)
-
FGFR3
- U
- Ulixertinib (ERK inhibitor)
-
BRAF, HRAS, KRAS, MAP2K1, NRAS, PTPN11, NF1
- Uprosertib (pan-AKT inhibitor)
-
AKT2, AKT3
- V
- Valproic acid (HDAC inhibitor)
-
KDM6A
- Vandetanib (EGFR inhibitor, second generation, RET inhibitor, VEGFR2 inhibitor)
-
RET
- Varegacestat (gamma secretase inhibitor)
-
APC, CTNNB1
- VE-821 (ATR inhibitor)
-
CHEK1, TP53
- VE-821 + Cisplatin
-
ATM, TP53
- Vebreltinib (MET inhibitor, type 1)
-
MET
- Veliparib (PARP inhibitor)
-
BRCA1, BRCA2, Homologous Recombination Deficiency Score (HRD), ARID1A, CDK12, DAXX, FANCD2, IDH1, IDH2
- Veliparib + Carboplatin + Paclitaxel
-
BRCA1, BRCA2
- Vemurafenib (BRAF V600 inhibitor)
-
BRAF, MAP2K1, MAP2K1+BRAF, RAF1
- Vemurafenib + Cobimetinib
-
BRAF, RASA1
- Vemurafenib + Obinutuzumab
-
BRAF
- Venetoclax (BCL2 inhibitor)
-
BCL2
- Venetoclax + Fulvestrant
-
ESR1 (ER)
- Venetoclax + Rituximab
-
BCL2
- Vimseltinib (CSF1R inhibitor)
-
CSF1
- Vismodegib (SMO inhibitor, first generation)
-
PTCH1, BRAF, GLI1, GLI2, HRAS, SMO, SUFU
- Vistusertib (mTORC1/mTORC2 inhibitor)
-
RICTOR
- Vistusertib + Anastrozole
-
ESR1 (ER)
- Vociprotafib (SHP2 inhibitor)
-
KRAS
- Vociprotafib + Cobimetinib
-
BRAF, KRAS, NF1
- Volasertib
-
RB1
- Vorasidenib (IDH1/IDH2 mutant selective inhibitor)
-
IDH1, IDH2
- Vorinostat (HDAC inhibitor)
-
KDM6A
- VRN101099 (ERBB2 inhibitor, second generation)
-
ERBB2 (HER2)
- VS-4718 (FAK inhibitor)
-
NF2
- VT104 (TEAD palmitoylation inhibitor)
-
NF2
- VT3989 (TEAD palmitoylation inhibitor)
-
NF2
- VVD-442 (RAS-PI3Kalpha inhibitor)
-
ERBB2 (HER2), KRAS
- VX-970 (ATR inhibitor)
-
ATM, MYB
- VX11E (ERK inhibitor)
-
MAP2K2, MAPK1 (ERK2), MAPK3 (ERK1)
- X
- Xaluritamig (bispecific T-cell engager, STEAP1-targeting)
-
STEAP1
- Y
- YH32367 (bispecific ERBB2/4-1BB antibody)
-
ERBB2 (HER2)
- YL201
-
CD276 (B7-H3)
- Z
- Zanidatamab (bispecific ERBB2/ERBB2 antibody)
-
ERBB2 (HER2)
- ZEN-3694 + Talazoparib
-
BRCA1+BRCA2
- Zenocutuzumab (bispecific ERBB2/ERBB3 antibody)
-
NRG1
- Ziftomenib (menin-MLL1 inhibitor)
-
KMT2A, NPM1
- Zipalertinib (EGFR inhibitor, exon 20 selective)
-
EGFR
- ZN-1041 (ERBB2 inhibitor)
-
ERBB2 (HER2)
- Zolbetuximab (anti-CLDN18.2 monoclonal antibody)
-
CLDN18
- Zolbetuximab + CAPOX
-
CLDN18+ERBB2 (HER2)
- Zolbetuximab + FOLFOX
-
CLDN18+ERBB2 (HER2), CLDN18
- Zolbetuximab + Pembrolizumab
-
CLDN18
- Zoligratinib (FGFR1/2/3 inhibitor, reversible)
-
FGFR1, FGFR2, FGFR3
- Zongertinib (ERBB2 inhibitor, second generation)
-
ERBB2 (HER2), NRG1, EGFR
- Zorifertinib (EGFR inhibitor, third generation)
-
EGFR
- Zotizalkib (ALK inhibitor, fourth generation)
-
ALK
- Zurletrectinib (TRK inhibitor, second generation)
-
NTRK3